Inhibitors of EGFR and methods of use thereof
US12161649B2 · kind B2 · utility
0Cited by
2References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2019 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Apr 10, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0012
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers thereof, which modulate the activity of EGFR, a pharmaceutical composition comprising said compounds, and methods of treating or preventing a disease in which EGFR plays a role.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.